Search
Lyell Immunopharma's CEO on the future of TIL and CAR-T therapies for solid tumor targets
On the heels of a historic recent approval for the class, Lynn Seely describes the science behind TIL therapies.
Feb 26, 2024
top of page
Search
Follow BiotechTV
Also look for unique social pages for BiotechTV U.
.png){kind=logo}
Sponsor Spotlight
Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.
bottom of page